ES2498043T3 - Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas - Google Patents

Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas Download PDF

Info

Publication number: ES2498043T3
Authority: ES; Spain
Prior art keywords: methyl; yloxy; pyridin; piperazin; piperazine
Prior art date: 2006-06-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07809388.7T

Other languages

English (en)

Spanish (es)

Inventor

Roger B. Clark

Daniel Elbaum

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chiesi USA Inc

Original Assignee

Cornerstone Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-06

Filing date

2007-06-06

Publication date

2014-09-24

2007-06-06 Application filed by Cornerstone Therapeutics Inc filed Critical Cornerstone Therapeutics Inc

2014-09-24 Application granted granted Critical

2014-09-24 Publication of ES2498043T3 publication Critical patent/ES2498043T3/es

Status Active legal-status Critical Current

2027-06-06 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims description 40
239000008194 pharmaceutical composition Substances 0.000 title claims description 16
150000004885 piperazines Chemical class 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 284
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract description 91
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims abstract description 81
125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 51
229910052717 sulfur Inorganic materials 0.000 claims abstract description 38
229910052760 oxygen Inorganic materials 0.000 claims abstract description 33
125000005865 C2-C10alkynyl group Chemical group 0.000 claims abstract description 31
229910052799 carbon Inorganic materials 0.000 claims abstract description 30
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 28
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 27
229910002091 carbon monoxide Inorganic materials 0.000 claims abstract description 7
-1 (pyridin-3-yloxy) methyl Chemical group 0.000 claims description 479
IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims description 199
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
125000001072 heteroaryl group Chemical group 0.000 claims description 98
125000003118 aryl group Chemical group 0.000 claims description 82
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 56
125000005843 halogen group Chemical group 0.000 claims description 46
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
150000001602 bicycloalkyls Chemical group 0.000 claims description 33
125000005842 heteroatom Chemical group 0.000 claims description 32
WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 25
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 23
125000001188 haloalkyl group Chemical group 0.000 claims description 23
125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 23
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 23
238000011282 treatment Methods 0.000 claims description 22
RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 claims description 21
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 19
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 17
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 15
125000000217 alkyl group Chemical group 0.000 claims description 15
125000003107 substituted aryl group Chemical group 0.000 claims description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
NDDBJQAYFMWCAO-UHFFFAOYSA-N 2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound O=CN1CCNCC1COC1=CC=CN=C1 NDDBJQAYFMWCAO-UHFFFAOYSA-N 0.000 claims description 13
230000004968 inflammatory condition Effects 0.000 claims description 13
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 10
206010040047 Sepsis Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
208000024827 Alzheimer disease Diseases 0.000 claims description 9
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 7
101100134925 Gallus gallus COR6 gene Proteins 0.000 claims description 7
208000002193 Pain Diseases 0.000 claims description 7
206010033645 Pancreatitis Diseases 0.000 claims description 7
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 7
210000003169 central nervous system Anatomy 0.000 claims description 7
206010034674 peritonitis Diseases 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
206010069351 acute lung injury Diseases 0.000 claims description 6
230000036407 pain Effects 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
208000011580 syndromic disease Diseases 0.000 claims description 6
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 5
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
208000019901 Anxiety disease Diseases 0.000 claims description 5
208000018737 Parkinson disease Diseases 0.000 claims description 5
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 5
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
208000000323 Tourette Syndrome Diseases 0.000 claims description 4
208000016620 Tourette disease Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
235000019256 formaldehyde Nutrition 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
CNHVJRWHCMOHBR-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)N1C(COC=2C=NC=CC=2)CNCC1 CNHVJRWHCMOHBR-UHFFFAOYSA-N 0.000 claims description 3
JFWOCEJLRQNSEH-GFCCVEGCSA-N 2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound C([C@@H]1N(CCNC1)C=1OC2=CC=CN=C2N=1)OC1=CC=CN=C1 JFWOCEJLRQNSEH-GFCCVEGCSA-N 0.000 claims description 3
JFWOCEJLRQNSEH-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound C1NCCN(C=2OC3=CC=CN=C3N=2)C1COC1=CC=CN=C1 JFWOCEJLRQNSEH-UHFFFAOYSA-N 0.000 claims description 3
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 3
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 3
RRHKQLVLCRFUIM-UHFFFAOYSA-N 5-[3-(4-bromophenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(Br)=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 RRHKQLVLCRFUIM-UHFFFAOYSA-N 0.000 claims description 3
ZQGUAEAHRHRVKK-UHFFFAOYSA-N 5-[3-(4-methoxyphenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 ZQGUAEAHRHRVKK-UHFFFAOYSA-N 0.000 claims description 3
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
206010014824 Endotoxic shock Diseases 0.000 claims description 3
208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
206010040070 Septic Shock Diseases 0.000 claims description 3
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 3
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
208000024908 graft versus host disease Diseases 0.000 claims description 3
208000031225 myocardial ischemia Diseases 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
SCFUQUYDYXEQDE-UHFFFAOYSA-N (1-phenylcyclopropyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1CC1(C=1C=CC=CC=1)C(=O)N1CCNCC1COC1=CC=CN=C1 SCFUQUYDYXEQDE-UHFFFAOYSA-N 0.000 claims description 2
YXWWVOZZRMPMDO-UHFFFAOYSA-N (2,4-dimethoxyphenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound COC1=CC(OC)=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 YXWWVOZZRMPMDO-UHFFFAOYSA-N 0.000 claims description 2
ABUXOOYOXCOUIS-UHFFFAOYSA-N (2-chloro-1,3-thiazol-4-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound S1C(Cl)=NC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1 ABUXOOYOXCOUIS-UHFFFAOYSA-N 0.000 claims description 2
WACTVYNFHJLWCL-UHFFFAOYSA-N (2-methoxyphenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound COC1=CC=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 WACTVYNFHJLWCL-UHFFFAOYSA-N 0.000 claims description 2
MFGJUQBOFRTFKT-UHFFFAOYSA-N (2-morpholin-4-yl-1,3-oxazol-4-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1OC(N2CCOCC2)=NC=1C(=O)N1CCNCC1COC1=CC=CN=C1 MFGJUQBOFRTFKT-UHFFFAOYSA-N 0.000 claims description 2
XZNAWWAEBUWLID-UHFFFAOYSA-N (2-phenyl-1,3-oxazol-4-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1OC(C=2C=CC=CC=2)=NC=1C(=O)N1CCNCC1COC1=CC=CN=C1 XZNAWWAEBUWLID-UHFFFAOYSA-N 0.000 claims description 2
UYKHJGHKVXWOMB-UHFFFAOYSA-N (2-phenyl-1,3-thiazol-4-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1SC(C=2C=CC=CC=2)=NC=1C(=O)N1CCNCC1COC1=CC=CN=C1 UYKHJGHKVXWOMB-UHFFFAOYSA-N 0.000 claims description 2
ONYQCGSWLCIAHJ-UHFFFAOYSA-N (3-bromophenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound BrC1=CC=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1 ONYQCGSWLCIAHJ-UHFFFAOYSA-N 0.000 claims description 2
XYGKIRAKPCRLTN-UHFFFAOYSA-N (3-chloro-2-fluorophenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound FC1=C(Cl)C=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 XYGKIRAKPCRLTN-UHFFFAOYSA-N 0.000 claims description 2
WXRLKBYUANPFQT-UHFFFAOYSA-N (3-chlorophenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound ClC1=CC=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1 WXRLKBYUANPFQT-UHFFFAOYSA-N 0.000 claims description 2
BWSARKOAMVWPBQ-UHFFFAOYSA-N (4-methoxyphenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 BWSARKOAMVWPBQ-UHFFFAOYSA-N 0.000 claims description 2
IREAGJAHVNINIU-UHFFFAOYSA-N (4-methyl-2-phenyl-1,3-oxazol-5-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound CC=1N=C(C=2C=CC=CC=2)OC=1C(=O)N1CCNCC1COC1=CC=CN=C1 IREAGJAHVNINIU-UHFFFAOYSA-N 0.000 claims description 2
MYVXXOMGWFWOCN-LLVKDONJSA-N (5-bromofuran-2-yl)-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound O1C(Br)=CC=C1C(=O)N1[C@@H](COC=2C=NC=CC=2)CNCC1 MYVXXOMGWFWOCN-LLVKDONJSA-N 0.000 claims description 2
LRVJESPXGRMMEV-UHFFFAOYSA-N (5-bromothiophen-2-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound S1C(Br)=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 LRVJESPXGRMMEV-UHFFFAOYSA-N 0.000 claims description 2
ULGUVLFRXKUUAV-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound O1C(C)=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=N1 ULGUVLFRXKUUAV-UHFFFAOYSA-N 0.000 claims description 2
SRDWLVXJGJOUCG-QGZVFWFLSA-N (5-phenylfuran-2-yl)-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C([C@H]1CNCCN1C(=O)C=1OC(=CC=1)C=1C=CC=CC=1)OC1=CC=CN=C1 SRDWLVXJGJOUCG-QGZVFWFLSA-N 0.000 claims description 2
MECSWWQYYYLRAM-UHFFFAOYSA-N (6-chloropyridin-2-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound ClC1=CC=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=N1 MECSWWQYYYLRAM-UHFFFAOYSA-N 0.000 claims description 2
YBVXXYVXULDRJO-UHFFFAOYSA-N 1-(4-bromophenyl)sulfonyl-2-(pyridin-3-yloxymethyl)piperazine Chemical compound C1=CC(Br)=CC=C1S(=O)(=O)N1C(COC=2C=NC=CC=2)CNCC1 YBVXXYVXULDRJO-UHFFFAOYSA-N 0.000 claims description 2
YBVUTECZPMIEFP-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonyl-2-(pyridin-3-yloxymethyl)piperazine Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1C(COC=2C=NC=CC=2)CNCC1 YBVUTECZPMIEFP-UHFFFAOYSA-N 0.000 claims description 2
PDGIUVURUWMHJQ-UHFFFAOYSA-N 1-(4-methoxyphenyl)sulfonyl-2-(pyridin-3-yloxymethyl)piperazine Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C(COC=2C=NC=CC=2)CNCC1 PDGIUVURUWMHJQ-UHFFFAOYSA-N 0.000 claims description 2
WGAHVRMVLAOSAK-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-(pyridin-3-yloxymethyl)piperazine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1CCNCC1COC1=CC=CN=C1 WGAHVRMVLAOSAK-UHFFFAOYSA-N 0.000 claims description 2
WFNOJPPLLOPNIM-UHFFFAOYSA-N 1-[5-(4-methylphenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine Chemical compound C1=CC(C)=CC=C1C1=CC=C(N2C(CNCC2)COC=2C=NC=CC=2)O1 WFNOJPPLLOPNIM-UHFFFAOYSA-N 0.000 claims description 2
LUKQQWSYTMBGKA-UHFFFAOYSA-N 1-benzofuran-2-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C2=CC=CC=C2OC=1C(=O)N1CCNCC1COC1=CC=CN=C1 LUKQQWSYTMBGKA-UHFFFAOYSA-N 0.000 claims description 2
ZCLQVGPVZONKOV-UHFFFAOYSA-N 1h-indol-2-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)N1CCNCC1COC1=CC=CN=C1 ZCLQVGPVZONKOV-UHFFFAOYSA-N 0.000 claims description 2
LQKYJGYJYBVUHW-UHFFFAOYSA-N 1h-indol-5-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C=C2NC=CC2=CC=1C(=O)N1CCNCC1COC1=CC=CN=C1 LQKYJGYJYBVUHW-UHFFFAOYSA-N 0.000 claims description 2
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
CCYPXYVUBKLTGM-UHFFFAOYSA-N 2-(2-anilino-1,3-oxazol-4-yl)-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound O=CN1CCNCC1(C=1N=C(NC=2C=CC=CC=2)OC=1)COC1=CC=CN=C1 CCYPXYVUBKLTGM-UHFFFAOYSA-N 0.000 claims description 2
XUAUCLUCICUCCY-UHFFFAOYSA-N 2-(3-methylphenyl)-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-3h-1,3-oxazole-4-carbaldehyde Chemical compound CC1=CC=CC(C2(OC=C(C=O)N2)N2C(CNCC2)COC=2C=NC=CC=2)=C1 XUAUCLUCICUCCY-UHFFFAOYSA-N 0.000 claims description 2
BVVJLIQCUAOEIC-UHFFFAOYSA-N 2-(4-methylphenyl)-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-3h-1,3-thiazole-4-carbaldehyde Chemical compound C1=CC(C)=CC=C1C1(N2C(CNCC2)COC=2C=NC=CC=2)SC=C(C=O)N1 BVVJLIQCUAOEIC-UHFFFAOYSA-N 0.000 claims description 2
YEUQXQLRMFNGEE-UHFFFAOYSA-N 2-(6-hydroxy-1,3-benzothiazol-2-yl)-3-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound OC1=CC2=C(N=C(S2)C2N(CCNC2COC=2C=NC=CC=2)C=O)C=C1 YEUQXQLRMFNGEE-UHFFFAOYSA-N 0.000 claims description 2
JFWOCEJLRQNSEH-LBPRGKRZSA-N 2-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound C([C@H]1N(CCNC1)C=1OC2=CC=CN=C2N=1)OC1=CC=CN=C1 JFWOCEJLRQNSEH-LBPRGKRZSA-N 0.000 claims description 2
XWDQNZJZDBGGGD-UHFFFAOYSA-N 2-[2-(2-methoxyphenyl)-1,3-oxazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound COC1=CC=CC=C1C1=NC(C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=CO1 XWDQNZJZDBGGGD-UHFFFAOYSA-N 0.000 claims description 2
VHBUZQWAWSQOEN-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)-1,3-oxazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(N=2)C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=C1 VHBUZQWAWSQOEN-UHFFFAOYSA-N 0.000 claims description 2
QDXSZBUCJLQAAP-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(F)=CC=C1C1=NC(C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=CS1 QDXSZBUCJLQAAP-UHFFFAOYSA-N 0.000 claims description 2
YOWAJQNLICRAFV-UHFFFAOYSA-N 2-[2-(4-methoxyanilino)-1,3-oxazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(OC)=CC=C1NC1=NC(C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=CO1 YOWAJQNLICRAFV-UHFFFAOYSA-N 0.000 claims description 2
QXCJQGJSLVPKJN-UHFFFAOYSA-N 2-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=NC(C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=CS1 QXCJQGJSLVPKJN-UHFFFAOYSA-N 0.000 claims description 2
YCCSQHDGXCCVDQ-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound C1NCCN(C=2SC3=CC=CC=C3N=2)C1COC1=CC=CN=C1 YCCSQHDGXCCVDQ-UHFFFAOYSA-N 0.000 claims description 2
KGULBAINNSJUHA-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-thiazole Chemical compound C1NCCN(C=2SC=CN=2)C1COC1=CC=CN=C1 KGULBAINNSJUHA-UHFFFAOYSA-N 0.000 claims description 2
MMKNVMWUWPARRY-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-2-[4-(trifluoromethoxy)phenyl]-3h-1,3-thiazole-4-carbaldehyde Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1(N2C(CNCC2)COC=2C=NC=CC=2)SC=C(C=O)N1 MMKNVMWUWPARRY-UHFFFAOYSA-N 0.000 claims description 2
QTWOJDSUDHJKHR-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-5-[4-(trifluoromethoxy)phenyl]-3h-furan-2-carbaldehyde Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CCC(N2C(CNCC2)COC=2C=NC=CC=2)(C=O)O1 QTWOJDSUDHJKHR-UHFFFAOYSA-N 0.000 claims description 2
GAVUBXXMNWRQQF-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-6-(trifluoromethyl)-1,3-benzothiazole Chemical compound S1C2=CC(C(F)(F)F)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 GAVUBXXMNWRQQF-UHFFFAOYSA-N 0.000 claims description 2
AFOWPYQXAWFUNW-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-6-(trifluoromethyl)-[1,3]thiazolo[4,5-b]pyridine Chemical compound S1C2=CC(C(F)(F)F)=CN=C2N=C1N1CCNCC1COC1=CC=CN=C1 AFOWPYQXAWFUNW-UHFFFAOYSA-N 0.000 claims description 2
KJVWZDRTDHNCHE-UHFFFAOYSA-N 2-[2-[(2-methylpyridin-3-yl)oxymethyl]piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound CC1=NC=CC=C1OCC1N(C=2OC3=CC=CN=C3N=2)CCNC1 KJVWZDRTDHNCHE-UHFFFAOYSA-N 0.000 claims description 2
JKBNHPNUIZGEQC-UHFFFAOYSA-N 2-[2-[(3-fluorophenoxy)methyl]piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound FC1=CC=CC(OCC2N(CCNC2)C=2OC3=CC=CN=C3N=2)=C1 JKBNHPNUIZGEQC-UHFFFAOYSA-N 0.000 claims description 2
VWLJEDWHPJZTDC-UHFFFAOYSA-N 2-[2-[(5-chloropyridin-3-yl)oxymethyl]piperazin-1-yl]-6-methoxy-1,3-benzothiazole Chemical compound S1C2=CC(OC)=CC=C2N=C1N1CCNCC1COC1=CN=CC(Cl)=C1 VWLJEDWHPJZTDC-UHFFFAOYSA-N 0.000 claims description 2
YNNUSGIPVFPVBX-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound CN1CCCC1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-UHFFFAOYSA-N 0.000 claims description 2
ONEWOTWOLLAKKR-UHFFFAOYSA-N 2-[3-(2-fluorophenyl)pyridin-2-yl]-6-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound FC1=CC=CC=C1C1=CC=CN=C1C1N(C=O)C(COC=2C=NC=CC=2)CNC1 ONEWOTWOLLAKKR-UHFFFAOYSA-N 0.000 claims description 2
PHAVQBBYNKQZJI-UHFFFAOYSA-N 2-[3-(3-methoxyphenyl)pyridin-2-yl]-6-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound COC1=CC=CC(C=2C(=NC=CC=2)C2N(C(COC=3C=NC=CC=3)CNC2)C=O)=C1 PHAVQBBYNKQZJI-UHFFFAOYSA-N 0.000 claims description 2
SYKYORAAGDHDEQ-UHFFFAOYSA-N 2-[3-(4-methoxyphenyl)pyridin-2-yl]-6-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=CC=CN=C1C1N(C=O)C(COC=2C=NC=CC=2)CNC1 SYKYORAAGDHDEQ-UHFFFAOYSA-N 0.000 claims description 2
CHDCCHSKFNTLKE-UHFFFAOYSA-N 2-phenoxy-1-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]ethanone Chemical compound C1CNCC(COC=2C=NC=CC=2)N1C(=O)COC1=CC=CC=C1 CHDCCHSKFNTLKE-UHFFFAOYSA-N 0.000 claims description 2
QBEMNXDITWAPCB-UHFFFAOYSA-N 2-phenyl-1-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]ethanone Chemical compound C1CNCC(COC=2C=NC=CC=2)N1C(=O)CC1=CC=CC=C1 QBEMNXDITWAPCB-UHFFFAOYSA-N 0.000 claims description 2
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
WNNSAUSDBPUZAJ-UHFFFAOYSA-N 3-phenyl-1-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]propan-1-one Chemical compound C1CNCC(COC=2C=NC=CC=2)N1C(=O)CCC1=CC=CC=C1 WNNSAUSDBPUZAJ-UHFFFAOYSA-N 0.000 claims description 2
BALDUDYARYXJIK-GFCCVEGCSA-N 4,6-difluoro-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound C([C@H]1CNCCN1C1=NC2=C(F)C=C(C=C2S1)F)OC1=CC=CN=C1 BALDUDYARYXJIK-GFCCVEGCSA-N 0.000 claims description 2
FZAYRVCHXUMWQV-UHFFFAOYSA-N 4,6-difluoro-2-[2-[(2-methylpyridin-3-yl)oxymethyl]piperazin-1-yl]-1,3-benzothiazole Chemical compound CC1=NC=CC=C1OCC1N(C=2SC3=CC(F)=CC(F)=C3N=2)CCNC1 FZAYRVCHXUMWQV-UHFFFAOYSA-N 0.000 claims description 2
WSMGAZLDTRDIFD-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-thiazole Chemical compound C1=CC(Cl)=CC=C1C1=CSC(N2C(CNCC2)COC=2C=NC=CC=2)=N1 WSMGAZLDTRDIFD-UHFFFAOYSA-N 0.000 claims description 2
RQNIYTAOXNAXSR-GFCCVEGCSA-N 4-fluoro-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound C([C@H]1CNCCN1C=1SC=2C=CC=C(C=2N=1)F)OC1=CC=CN=C1 RQNIYTAOXNAXSR-GFCCVEGCSA-N 0.000 claims description 2
RQNIYTAOXNAXSR-UHFFFAOYSA-N 4-fluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound N=1C=2C(F)=CC=CC=2SC=1N1CCNCC1COC1=CC=CN=C1 RQNIYTAOXNAXSR-UHFFFAOYSA-N 0.000 claims description 2
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
CRILNVYQVLOETI-UHFFFAOYSA-N 4-methyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound N=1C=2C(C)=CC=CC=2OC=1N1CCNCC1COC1=CC=CN=C1 CRILNVYQVLOETI-UHFFFAOYSA-N 0.000 claims description 2
ZZHCENIAXZZTCD-LLVKDONJSA-N 5,6-difluoro-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound C([C@H]1CNCCN1C1=NC=2C=C(C(=CC=2S1)F)F)OC1=CC=CN=C1 ZZHCENIAXZZTCD-LLVKDONJSA-N 0.000 claims description 2
ZZHCENIAXZZTCD-UHFFFAOYSA-N 5,6-difluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C=2C=C(F)C(F)=CC=2N=C1N1CCNCC1COC1=CC=CN=C1 ZZHCENIAXZZTCD-UHFFFAOYSA-N 0.000 claims description 2
TYNQHVSOQHQRHY-UHFFFAOYSA-N 5-[3-(2,4-dichlorophenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound ClC1=CC(Cl)=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 TYNQHVSOQHQRHY-UHFFFAOYSA-N 0.000 claims description 2
NNRKLFUIMKJGJO-UHFFFAOYSA-N 5-[3-(2,5-dichlorophenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound ClC1=CC=C(Cl)C(C2=C(OC=C2)C2NCC(COC=3C=NC=CC=3)N(C=O)C2)=C1 NNRKLFUIMKJGJO-UHFFFAOYSA-N 0.000 claims description 2
JRNKFMFRNWYTHI-UHFFFAOYSA-N 5-[3-(2-chlorophenyl)thiophen-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound ClC1=CC=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)SC=C1 JRNKFMFRNWYTHI-UHFFFAOYSA-N 0.000 claims description 2
MQCWJDZMYBUBED-UHFFFAOYSA-N 5-[3-(2-methoxyphenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound COC1=CC=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 MQCWJDZMYBUBED-UHFFFAOYSA-N 0.000 claims description 2
PSVTXPIEOOEOGD-UHFFFAOYSA-N 5-[3-(3,4-dimethoxyphenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 PSVTXPIEOOEOGD-UHFFFAOYSA-N 0.000 claims description 2
FYGPTDNQRQSYJG-UHFFFAOYSA-N 5-[3-(3-chlorophenyl)thiophen-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound ClC1=CC=CC(C2=C(SC=C2)C2NCC(COC=3C=NC=CC=3)N(C=O)C2)=C1 FYGPTDNQRQSYJG-UHFFFAOYSA-N 0.000 claims description 2
UNOJABUJPIMXDF-UHFFFAOYSA-N 5-[3-(3-methoxyphenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound COC1=CC=CC(C2=C(OC=C2)C2NCC(COC=3C=NC=CC=3)N(C=O)C2)=C1 UNOJABUJPIMXDF-UHFFFAOYSA-N 0.000 claims description 2
AFMHUSVESUCSCF-CYBMUJFWSA-N 5-bromo-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@H]1CNCCN1C=1OC2=CC=C(C=C2N=1)Br)OC1=CC=CN=C1 AFMHUSVESUCSCF-CYBMUJFWSA-N 0.000 claims description 2
AFMHUSVESUCSCF-ZDUSSCGKSA-N 5-bromo-2-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@@H]1CNCCN1C=1OC2=CC=C(C=C2N=1)Br)OC1=CC=CN=C1 AFMHUSVESUCSCF-ZDUSSCGKSA-N 0.000 claims description 2
PVRZFFNSBLBTMK-UHFFFAOYSA-N 5-chloro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound N=1C2=CC(Cl)=CC=C2SC=1N1CCNCC1COC1=CC=CN=C1 PVRZFFNSBLBTMK-UHFFFAOYSA-N 0.000 claims description 2
SDXXZAOQKNZXMY-UHFFFAOYSA-N 5-chloro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound N=1C2=CC(Cl)=CC=C2OC=1N1CCNCC1COC1=CC=CN=C1 SDXXZAOQKNZXMY-UHFFFAOYSA-N 0.000 claims description 2
KCCYRCZTHZADKY-UHFFFAOYSA-N 5-fluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound N=1C2=CC(F)=CC=C2SC=1N1CCNCC1COC1=CC=CN=C1 KCCYRCZTHZADKY-UHFFFAOYSA-N 0.000 claims description 2
BHOVAOOOJKVCPM-CYBMUJFWSA-N 5-methoxy-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@H]1CNCCN1C=1OC2=CC=C(C=C2N=1)OC)OC1=CC=CN=C1 BHOVAOOOJKVCPM-CYBMUJFWSA-N 0.000 claims description 2
BHOVAOOOJKVCPM-ZDUSSCGKSA-N 5-methoxy-2-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@@H]1CNCCN1C=1OC2=CC=C(C=C2N=1)OC)OC1=CC=CN=C1 BHOVAOOOJKVCPM-ZDUSSCGKSA-N 0.000 claims description 2
SDUABLPTWFDAHS-UHFFFAOYSA-N 5-methoxy-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound N=1C2=CC(OC)=CC=C2SC=1N1CCNCC1COC1=CC=CN=C1 SDUABLPTWFDAHS-UHFFFAOYSA-N 0.000 claims description 2
AIVITGHKBHHEMC-CYBMUJFWSA-N 5-methyl-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound C([C@H]1CNCCN1C=1OC2=CC=C(N=C2N=1)C)OC1=CC=CN=C1 AIVITGHKBHHEMC-CYBMUJFWSA-N 0.000 claims description 2
JARKOPXYLQFPBF-UHFFFAOYSA-N 5-methyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1N1CCNCC1COC1=CC=CN=C1 JARKOPXYLQFPBF-UHFFFAOYSA-N 0.000 claims description 2
AIVITGHKBHHEMC-UHFFFAOYSA-N 5-methyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound N=1C2=NC(C)=CC=C2OC=1N1CCNCC1COC1=CC=CN=C1 AIVITGHKBHHEMC-UHFFFAOYSA-N 0.000 claims description 2
HHCWIFMEJHAZNP-LJQANCHMSA-N 5-phenyl-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@@H]1N(CCNC1)C=1OC2=CC=C(C=C2N=1)C=1C=CC=CC=1)OC1=CC=CN=C1 HHCWIFMEJHAZNP-LJQANCHMSA-N 0.000 claims description 2
ZEFDVSMGFNRANY-LLVKDONJSA-N 6,7-difluoro-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound C([C@H]1CNCCN1C1=NC2=CC=C(C(=C2S1)F)F)OC1=CC=CN=C1 ZEFDVSMGFNRANY-LLVKDONJSA-N 0.000 claims description 2
MHNZSPSOBMWKST-UHFFFAOYSA-N 6-bromo-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]thiazolo[4,5-b]pyridine Chemical compound S1C2=CC(Br)=CN=C2N=C1N1CCNCC1COC1=CC=CN=C1 MHNZSPSOBMWKST-UHFFFAOYSA-N 0.000 claims description 2
CHDXRQAPJOCKSI-UHFFFAOYSA-N 6-bromo-4-fluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound N=1C=2C(F)=CC(Br)=CC=2SC=1N1CCNCC1COC1=CC=CN=C1 CHDXRQAPJOCKSI-UHFFFAOYSA-N 0.000 claims description 2
OARKQPBOYXYUNX-UHFFFAOYSA-N 6-chloro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound O1C2=CC(Cl)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 OARKQPBOYXYUNX-UHFFFAOYSA-N 0.000 claims description 2
OEEVLYURDVGDRZ-UHFFFAOYSA-N 6-chloro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]thiazolo[4,5-b]pyridine Chemical compound S1C2=CC(Cl)=CN=C2N=C1N1CCNCC1COC1=CC=CN=C1 OEEVLYURDVGDRZ-UHFFFAOYSA-N 0.000 claims description 2
LSEAPQJYDYWCML-UHFFFAOYSA-N 6-chloro-2-[2-[(5-chloropyridin-3-yl)oxymethyl]piperazin-1-yl]-1,3-benzoxazole Chemical compound O1C2=CC(Cl)=CC=C2N=C1N1CCNCC1COC1=CN=CC(Cl)=C1 LSEAPQJYDYWCML-UHFFFAOYSA-N 0.000 claims description 2
PKPUZIAYPUBJTC-UHFFFAOYSA-N 6-fluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(F)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 PKPUZIAYPUBJTC-UHFFFAOYSA-N 0.000 claims description 2
ICZRDADPLBRUDW-UHFFFAOYSA-N 6-fluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound O1C2=CC(F)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 ICZRDADPLBRUDW-UHFFFAOYSA-N 0.000 claims description 2
OVJTVDMKFSMIMQ-CYBMUJFWSA-N 6-methoxy-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound C([C@H]1CNCCN1C1=NC2=CC=C(C=C2S1)OC)OC1=CC=CN=C1 OVJTVDMKFSMIMQ-CYBMUJFWSA-N 0.000 claims description 2
OVJTVDMKFSMIMQ-ZDUSSCGKSA-N 6-methoxy-2-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound C([C@@H]1CNCCN1C1=NC2=CC=C(C=C2S1)OC)OC1=CC=CN=C1 OVJTVDMKFSMIMQ-ZDUSSCGKSA-N 0.000 claims description 2
XYSRATNRZNDHDH-UHFFFAOYSA-N 6-methoxy-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound O1C2=CC(OC)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 XYSRATNRZNDHDH-UHFFFAOYSA-N 0.000 claims description 2
PHXJCUKYONGLIY-CQSZACIVSA-N 6-methyl-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@H]1CNCCN1C1=NC2=CC=C(C=C2O1)C)OC1=CC=CN=C1 PHXJCUKYONGLIY-CQSZACIVSA-N 0.000 claims description 2
WMTXHNNOKUFMQN-CYBMUJFWSA-N 6-methyl-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound C([C@H]1CNCCN1C1=NC2=NC=C(C=C2O1)C)OC1=CC=CN=C1 WMTXHNNOKUFMQN-CYBMUJFWSA-N 0.000 claims description 2
VGLUILQIUIMRGH-UHFFFAOYSA-N 6-methyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(C)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 VGLUILQIUIMRGH-UHFFFAOYSA-N 0.000 claims description 2
PHXJCUKYONGLIY-UHFFFAOYSA-N 6-methyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound O1C2=CC(C)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 PHXJCUKYONGLIY-UHFFFAOYSA-N 0.000 claims description 2
WMTXHNNOKUFMQN-UHFFFAOYSA-N 6-methyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound O1C2=CC(C)=CN=C2N=C1N1CCNCC1COC1=CC=CN=C1 WMTXHNNOKUFMQN-UHFFFAOYSA-N 0.000 claims description 2
ZZKXCALTBHHQHE-UHFFFAOYSA-N 6-propan-2-yl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(C(C)C)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 ZZKXCALTBHHQHE-UHFFFAOYSA-N 0.000 claims description 2
206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
206010019280 Heart failures Diseases 0.000 claims description 2
MTPKJFGFMXVRHM-MRXNPFEDSA-N [(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-[5-[4-(trifluoromethoxy)phenyl]furan-2-yl]methanone Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC=C(C(=O)N2[C@H](CNCC2)COC=2C=NC=CC=2)O1 MTPKJFGFMXVRHM-MRXNPFEDSA-N 0.000 claims description 2
BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 claims description 2
WMVDYALEISXEJK-UHFFFAOYSA-N [3-(4-fluorophenyl)phenyl]-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1=CC=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1 WMVDYALEISXEJK-UHFFFAOYSA-N 0.000 claims description 2
MAYHNSYERVXFNF-UHFFFAOYSA-N [3-(4-methoxyphenyl)phenyl]-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C1=CC=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1 MAYHNSYERVXFNF-UHFFFAOYSA-N 0.000 claims description 2
RDYINIOWNGXUHJ-UHFFFAOYSA-N [4-(4-chlorophenyl)phenyl]-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)C=C1 RDYINIOWNGXUHJ-UHFFFAOYSA-N 0.000 claims description 2
WUKKVBTVHSQHNW-UHFFFAOYSA-N [4-(4-methoxyphenyl)phenyl]-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)C=C1 WUKKVBTVHSQHNW-UHFFFAOYSA-N 0.000 claims description 2
GILGNHMYPPVIMI-QGZVFWFLSA-N [5-(4-methoxyphenyl)furan-2-yl]-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)N2[C@H](CNCC2)COC=2C=NC=CC=2)O1 GILGNHMYPPVIMI-QGZVFWFLSA-N 0.000 claims description 2
GILGNHMYPPVIMI-KRWDZBQOSA-N [5-(4-methoxyphenyl)furan-2-yl]-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(=O)N2[C@@H](CNCC2)COC=2C=NC=CC=2)O1 GILGNHMYPPVIMI-KRWDZBQOSA-N 0.000 claims description 2
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
230000006735 deficit Effects 0.000 claims description 2
OUOZQDQVKIEOSX-UHFFFAOYSA-N furan-3-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=COC=C1C(=O)N1CCNCC1COC1=CC=CN=C1 OUOZQDQVKIEOSX-UHFFFAOYSA-N 0.000 claims description 2
FHLKXBHAPXAFLT-UHFFFAOYSA-N morpholin-4-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1CNCC(COC=2C=NC=CC=2)N1C(=O)N1CCOCC1 FHLKXBHAPXAFLT-UHFFFAOYSA-N 0.000 claims description 2
FUTKEGVHXNVRCU-UHFFFAOYSA-N morpholin-4-yl-[2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-thiazol-4-yl]methanone Chemical compound C=1SC(N2C(CNCC2)COC=2C=NC=CC=2)=NC=1C(=O)N1CCOCC1 FUTKEGVHXNVRCU-UHFFFAOYSA-N 0.000 claims description 2
JERSYUAJLPTOHC-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-2-(pyridin-3-yloxymethyl)piperazine-1-carboxamide Chemical compound C=1C=C2N=CSC2=CC=1NC(=O)N1CCNCC1COC1=CC=CN=C1 JERSYUAJLPTOHC-UHFFFAOYSA-N 0.000 claims description 2
SXOYNPTUGTTYBB-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-[(2-methoxyphenoxy)methyl]piperazine-1-carboxamide Chemical compound COC1=CC=CC=C1OCC1N(C(=O)NC=2C=C(Cl)C(Cl)=CC=2)CCNC1 SXOYNPTUGTTYBB-UHFFFAOYSA-N 0.000 claims description 2
VEBNNEXLKSHEBQ-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-[(3-methoxyphenoxy)methyl]piperazine-1-carboxamide Chemical compound COC1=CC=CC(OCC2N(CCNC2)C(=O)NC=2C=C(Cl)C(Cl)=CC=2)=C1 VEBNNEXLKSHEBQ-UHFFFAOYSA-N 0.000 claims description 2
VVQXJVLEGVWSQE-UHFFFAOYSA-N n-(4-methoxyphenyl)-2-[(pyridin-3-ylamino)methyl]piperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1C(CNC=2C=NC=CC=2)CNCC1 VVQXJVLEGVWSQE-UHFFFAOYSA-N 0.000 claims description 2
SLLIVVSDPDWJTR-UHFFFAOYSA-N n-[4-(4-methoxyphenyl)phenyl]-2-(pyridin-3-yloxymethyl)piperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=C1)=CC=C1NC(=O)N1C(COC=2C=NC=CC=2)CNCC1 SLLIVVSDPDWJTR-UHFFFAOYSA-N 0.000 claims description 2
RVEKUEDQUHJENM-UHFFFAOYSA-N n-[[1-(5-bromopyrimidin-2-yl)piperazin-2-yl]methyl]pyridin-3-amine Chemical compound N1=CC(Br)=CN=C1N1C(CNC=2C=NC=CC=2)CNCC1 RVEKUEDQUHJENM-UHFFFAOYSA-N 0.000 claims description 2
BNRJKIVUNKAFNX-UHFFFAOYSA-N piperidin-1-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1CNCC(COC=2C=NC=CC=2)N1C(=O)N1CCCCC1 BNRJKIVUNKAFNX-UHFFFAOYSA-N 0.000 claims description 2
FDOXMFZCZGODNI-UHFFFAOYSA-N pyridin-3-yl formate Chemical compound O=COC1=CC=CN=C1 FDOXMFZCZGODNI-UHFFFAOYSA-N 0.000 claims description 2
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 claims 2
206010039966 Senile dementia Diseases 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
SXMUZPBUPTVGND-UHFFFAOYSA-N (2-phenylphenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1C(=O)N1CCNCC1COC1=CC=CN=C1 SXMUZPBUPTVGND-UHFFFAOYSA-N 0.000 claims 1
UZEMSVUPCMZPJZ-UHFFFAOYSA-N (3-methylfuran-2-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=COC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1C UZEMSVUPCMZPJZ-UHFFFAOYSA-N 0.000 claims 1
LDPCOTFTPJLCKY-UHFFFAOYSA-N (4-bromophenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(Br)=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 LDPCOTFTPJLCKY-UHFFFAOYSA-N 0.000 claims 1
AIANUZPAXXVFHE-UHFFFAOYSA-N (4-chlorophenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 AIANUZPAXXVFHE-UHFFFAOYSA-N 0.000 claims 1
MYVXXOMGWFWOCN-UHFFFAOYSA-N (5-bromofuran-2-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound O1C(Br)=CC=C1C(=O)N1C(COC=2C=NC=CC=2)CNCC1 MYVXXOMGWFWOCN-UHFFFAOYSA-N 0.000 claims 1
SRDWLVXJGJOUCG-KRWDZBQOSA-N (5-phenylfuran-2-yl)-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C([C@@H]1CNCCN1C(=O)C=1OC(=CC=1)C=1C=CC=CC=1)OC1=CC=CN=C1 SRDWLVXJGJOUCG-KRWDZBQOSA-N 0.000 claims 1
XNPGPGQVXXCCMK-UHFFFAOYSA-N (5-phenylthiophen-2-yl)-[2-(pyridin-2-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C=C(C=2C=CC=CC=2)SC=1C(=O)N1CCNCC1COC1=CC=CC=N1 XNPGPGQVXXCCMK-UHFFFAOYSA-N 0.000 claims 1
CTIQATDANQTQQJ-UHFFFAOYSA-N (6-phenylpyridin-2-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C=CC(C=2C=CC=CC=2)=NC=1C(=O)N1CCNCC1COC1=CC=CN=C1 CTIQATDANQTQQJ-UHFFFAOYSA-N 0.000 claims 1
XHZRFPKYJVGJFX-UHFFFAOYSA-N 1-[4-(6-methoxy-1,3-benzothiazol-2-yl)-3-(pyridin-3-yloxymethyl)piperazin-1-yl]ethanone Chemical compound S1C2=CC(OC)=CC=C2N=C1N1CCN(C(C)=O)CC1COC1=CC=CN=C1 XHZRFPKYJVGJFX-UHFFFAOYSA-N 0.000 claims 1
RRYHNWTWNMGARH-UHFFFAOYSA-N 1-phenyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]ethane-1,2-dione Chemical compound C=1C=CC=CC=1C(=O)C(=O)N1CCNCC1COC1=CC=CN=C1 RRYHNWTWNMGARH-UHFFFAOYSA-N 0.000 claims 1
IHKNOFQSZSFHIL-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]ethanone Chemical compound C1=CC(Cl)=CC=C1CC(=O)N1C(COC=2C=NC=CC=2)CNCC1 IHKNOFQSZSFHIL-UHFFFAOYSA-N 0.000 claims 1
MJPJYJOZFJLUIN-UHFFFAOYSA-N 2-(4-methoxyphenoxy)-1-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1OCC(=O)N1C(COC=2C=NC=CC=2)CNCC1 MJPJYJOZFJLUIN-UHFFFAOYSA-N 0.000 claims 1
QVHOHVGAHDKJPR-UHFFFAOYSA-N 2-(4-methylphenyl)-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-3h-1,3-oxazole-4-carbaldehyde Chemical compound C1=CC(C)=CC=C1C1(N2C(CNCC2)COC=2C=NC=CC=2)OC=C(C=O)N1 QVHOHVGAHDKJPR-UHFFFAOYSA-N 0.000 claims 1
OIZPYIZBDYGMNM-CYBMUJFWSA-N 2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@@H]1N(CCNC1)C=1OC2=CC=CC=C2N=1)OC1=CC=CN=C1 OIZPYIZBDYGMNM-CYBMUJFWSA-N 0.000 claims 1
OIZPYIZBDYGMNM-ZDUSSCGKSA-N 2-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@H]1N(CCNC1)C=1OC2=CC=CC=C2N=1)OC1=CC=CN=C1 OIZPYIZBDYGMNM-ZDUSSCGKSA-N 0.000 claims 1
ANQISWOKPPNHMO-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethoxy)piperazin-1-yl]-6-(trifluoromethyl)-1,3-benzothiazole Chemical compound S1C2=CC(C(F)(F)F)=CC=C2N=C1N1CCNCC1OCOC1=CC=CN=C1 ANQISWOKPPNHMO-UHFFFAOYSA-N 0.000 claims 1
VMIHOBSXIAJKLM-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazol-6-ol Chemical compound S1C2=CC(O)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 VMIHOBSXIAJKLM-UHFFFAOYSA-N 0.000 claims 1
OIZPYIZBDYGMNM-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C1NCCN(C=2OC3=CC=CC=C3N=2)C1COC1=CC=CN=C1 OIZPYIZBDYGMNM-UHFFFAOYSA-N 0.000 claims 1
XSPXRWDGIBWQQQ-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-5-(trifluoromethyl)-1,3-benzothiazole Chemical compound N=1C2=CC(C(F)(F)F)=CC=C2SC=1N1CCNCC1COC1=CC=CN=C1 XSPXRWDGIBWQQQ-UHFFFAOYSA-N 0.000 claims 1
BNTPAMPDFGZCLZ-UHFFFAOYSA-N 2-[3-(trifluoromethoxy)phenyl]-1,3-oxazole-4-carbaldehyde Chemical compound FC(F)(F)OC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BNTPAMPDFGZCLZ-UHFFFAOYSA-N 0.000 claims 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
RJYXOZOCHIDHMY-UHFFFAOYSA-N 4-(4-methoxyphenyl)-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-thiazole Chemical compound C1=CC(OC)=CC=C1C1=CSC(N2C(CNCC2)COC=2C=NC=CC=2)=N1 RJYXOZOCHIDHMY-UHFFFAOYSA-N 0.000 claims 1
XRJASIXPTPVTJW-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)-1,3-oxazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=NC(N2CC(COC=3C=NC=CC=3)N(C=O)CC2)=CO1 XRJASIXPTPVTJW-UHFFFAOYSA-N 0.000 claims 1
WQXLEQZAMXZDTN-UHFFFAOYSA-N 4-phenyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-thiazole Chemical compound C1NCCN(C=2SC=C(N=2)C=2C=CC=CC=2)C1COC1=CC=CN=C1 WQXLEQZAMXZDTN-UHFFFAOYSA-N 0.000 claims 1
CHASOHNZDYZFEJ-UHFFFAOYSA-N 5,6-dimethyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C=2C=C(C)C(C)=CC=2N=C1N1CCNCC1COC1=CC=CN=C1 CHASOHNZDYZFEJ-UHFFFAOYSA-N 0.000 claims 1
HESOILFLKLABLV-UHFFFAOYSA-N 5-(2-methylphenyl)furan-2-carbaldehyde Chemical compound CC1=CC=CC=C1C1=CC=C(C=O)O1 HESOILFLKLABLV-UHFFFAOYSA-N 0.000 claims 1
MZKKVYCPCXNGMH-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 MZKKVYCPCXNGMH-UHFFFAOYSA-N 0.000 claims 1
OZPLFKVRWHDDIP-UHFFFAOYSA-N 5-[3-(4-fluorophenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(F)=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 OZPLFKVRWHDDIP-UHFFFAOYSA-N 0.000 claims 1
VEKRXOQPIUTLCI-UHFFFAOYSA-N 5-[3-(4-propan-2-yloxyphenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(OC(C)C)=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 VEKRXOQPIUTLCI-UHFFFAOYSA-N 0.000 claims 1
VPYRAXYANHWDHL-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]furan-2-carbaldehyde Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=C(C=O)O1 VPYRAXYANHWDHL-UHFFFAOYSA-N 0.000 claims 1
AFMHUSVESUCSCF-UHFFFAOYSA-N 5-bromo-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound N=1C2=CC(Br)=CC=C2OC=1N1CCNCC1COC1=CC=CN=C1 AFMHUSVESUCSCF-UHFFFAOYSA-N 0.000 claims 1
GCIOQQRGNQUYAI-UHFFFAOYSA-N 5-fluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound N=1C2=CC(F)=CC=C2OC=1N1CCNCC1COC1=CC=CN=C1 GCIOQQRGNQUYAI-UHFFFAOYSA-N 0.000 claims 1
HHCWIFMEJHAZNP-UHFFFAOYSA-N 5-phenyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C1NCCN(C=2OC3=CC=C(C=C3N=2)C=2C=CC=CC=2)C1COC1=CC=CN=C1 HHCWIFMEJHAZNP-UHFFFAOYSA-N 0.000 claims 1
QXUMUVOKKODEOL-UHFFFAOYSA-N 6-chloro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(Cl)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 QXUMUVOKKODEOL-UHFFFAOYSA-N 0.000 claims 1
XYSRATNRZNDHDH-ZDUSSCGKSA-N 6-methoxy-2-[(2s)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@@H]1CNCCN1C1=NC2=CC=C(C=C2O1)OC)OC1=CC=CN=C1 XYSRATNRZNDHDH-ZDUSSCGKSA-N 0.000 claims 1
208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
208000030886 Traumatic Brain injury Diseases 0.000 claims 1
208000029028 brain injury Diseases 0.000 claims 1
IQQIPCMWAXSPPY-UHFFFAOYSA-N furan-2-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C=COC=1C(=O)N1CCNCC1COC1=CC=CN=C1 IQQIPCMWAXSPPY-UHFFFAOYSA-N 0.000 claims 1
208000013403 hyperactivity Diseases 0.000 claims 1
IPAHKNWLHYRCOX-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-[[4-(trifluoromethoxy)phenoxy]methyl]piperazine-1-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1OCC1N(C(=O)NC=2C=C(Cl)C(Cl)=CC=2)CCNC1 IPAHKNWLHYRCOX-UHFFFAOYSA-N 0.000 claims 1
ARVIRZZBEFYMAQ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[(4-methoxyphenoxy)methyl]piperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1OCC1N(C(=O)NC=2C=CC(Cl)=CC=2)CCNC1 ARVIRZZBEFYMAQ-UHFFFAOYSA-N 0.000 claims 1
LCPUWJQVMSRZNG-UHFFFAOYSA-N n-(4-methoxyphenyl)-2-(phenoxymethyl)piperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1C(COC=2C=CC=CC=2)CNCC1 LCPUWJQVMSRZNG-UHFFFAOYSA-N 0.000 claims 1
230000009529 traumatic brain injury Effects 0.000 claims 1
230000000472 traumatic effect Effects 0.000 claims 1
125000005647 linker group Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 361
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 250
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 218
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 213
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 209
235000019439 ethyl acetate Nutrition 0.000 description 180
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 131
244000257039 Duranta repens Species 0.000 description 129
239000000463 material Substances 0.000 description 128
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 109
239000007832 Na2SO4 Substances 0.000 description 108
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 108
229910052938 sodium sulfate Inorganic materials 0.000 description 108
235000011152 sodium sulphate Nutrition 0.000 description 108
239000011541 reaction mixture Substances 0.000 description 88
125000005605 benzo group Chemical group 0.000 description 87
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 86
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 70
239000000543 intermediate Substances 0.000 description 62
230000002829 reductive effect Effects 0.000 description 60
239000000203 mixture Substances 0.000 description 58
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
238000003786 synthesis reaction Methods 0.000 description 49
230000015572 biosynthetic process Effects 0.000 description 48
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 47
239000000243 solution Substances 0.000 description 47
239000002585 base Substances 0.000 description 43
239000007787 solid Substances 0.000 description 42
241001442234 Cosa Species 0.000 description 39
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 39
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 33
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 30
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 29
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
239000000047 product Substances 0.000 description 28
239000000284 extract Substances 0.000 description 26
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
238000001816 cooling Methods 0.000 description 23
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 22
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 22
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 22
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
241001139947 Mida Species 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
241001459693 Dipterocarpus zeylanicus Species 0.000 description 18
239000007864 aqueous solution Substances 0.000 description 17
IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
238000009472 formulation Methods 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical group CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
239000012267 brine Substances 0.000 description 16
239000000460 chlorine Substances 0.000 description 16
238000004440 column chromatography Methods 0.000 description 16
238000010438 heat treatment Methods 0.000 description 16
238000000746 purification Methods 0.000 description 16
102000005962 receptors Human genes 0.000 description 16
108020003175 receptors Proteins 0.000 description 16
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 15
102000004127 Cytokines Human genes 0.000 description 15
108090000695 Cytokines Proteins 0.000 description 15
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
125000005587 carbonate group Chemical group 0.000 description 15
241000670727 Amida Species 0.000 description 14
241000124008 Mammalia Species 0.000 description 14
229910000027 potassium carbonate Inorganic materials 0.000 description 14
235000015320 potassium carbonate Nutrition 0.000 description 14
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 13
240000001987 Pyrus communis Species 0.000 description 13
GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 12
102100040247 Tumor necrosis factor Human genes 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
238000001914 filtration Methods 0.000 description 12
229910052763 palladium Inorganic materials 0.000 description 12
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
239000000443 aerosol Substances 0.000 description 11
208000015114 central nervous system disease Diseases 0.000 description 11
125000006239 protecting group Chemical group 0.000 description 11
239000011734 sodium Substances 0.000 description 11
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 10
239000012317 TBTU Substances 0.000 description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
230000001012 protector Effects 0.000 description 10
238000010992 reflux Methods 0.000 description 10
235000017557 sodium bicarbonate Nutrition 0.000 description 10
229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
239000003054 catalyst Substances 0.000 description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
239000003921 oil Substances 0.000 description 9
235000019198 oils Nutrition 0.000 description 9
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
229910052794 bromium Inorganic materials 0.000 description 8
125000004432 carbon atom Chemical group C* 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
229910052801 chlorine Inorganic materials 0.000 description 8
YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 8
230000035620 dolor Effects 0.000 description 8
239000007789 gas Substances 0.000 description 8
239000000499 gel Substances 0.000 description 8
239000010410 layer Substances 0.000 description 8
210000004962 mammalian cell Anatomy 0.000 description 8
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
125000001424 substituent group Chemical group 0.000 description 8
239000000725 suspension Substances 0.000 description 8
238000004809 thin layer chromatography Methods 0.000 description 8
101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 7
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
108700010013 HMGB1 Proteins 0.000 description 7
101150021904 HMGB1 gene Proteins 0.000 description 7
102100037907 High mobility group protein B1 Human genes 0.000 description 7
238000005481 NMR spectroscopy Methods 0.000 description 7
108010058846 Ovalbumin Proteins 0.000 description 7
206010009887 colitis Diseases 0.000 description 7
229910052500 inorganic mineral Inorganic materials 0.000 description 7
239000011707 mineral Substances 0.000 description 7
235000010755 mineral Nutrition 0.000 description 7
229940092253 ovalbumin Drugs 0.000 description 7
229910000104 sodium hydride Inorganic materials 0.000 description 7
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 7
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
108090001005 Interleukin-6 Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
241000718541 Tetragastris balsamifera Species 0.000 description 6
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
239000006071 cream Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
208000008384 ileus Diseases 0.000 description 6
230000000770 proinflammatory effect Effects 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
239000002904 solvent Substances 0.000 description 6
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
240000002319 Citrus sinensis Species 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
241001521328 Ruta Species 0.000 description 5
235000003976 Ruta Nutrition 0.000 description 5
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 5
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 5
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
230000002685 pulmonary effect Effects 0.000 description 5
235000005806 ruta Nutrition 0.000 description 5
238000003756 stirring Methods 0.000 description 5
125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 4
FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 4
241000238366 Cephalopoda Species 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
102000003810 Interleukin-18 Human genes 0.000 description 4
108090000171 Interleukin-18 Proteins 0.000 description 4
108090001007 Interleukin-8 Proteins 0.000 description 4
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
241001466077 Salina Species 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
241000009298 Trigla lyra Species 0.000 description 4
WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 4
239000000556 agonist Substances 0.000 description 4
125000003342 alkenyl group Chemical group 0.000 description 4
125000000304 alkynyl group Chemical group 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
239000002024 ethyl acetate extract Substances 0.000 description 4
235000003599 food sweetener Nutrition 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
238000007654 immersion Methods 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
235000010446 mineral oil Nutrition 0.000 description 4
208000004296 neuralgia Diseases 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
125000004193 piperazinyl group Chemical group 0.000 description 4
VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
IIZGWFQKLVCLLA-UHFFFAOYSA-N 1,4-bis[(2-methylpropan-2-yl)oxycarbonyl]piperazine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C(C(O)=O)C1 IIZGWFQKLVCLLA-UHFFFAOYSA-N 0.000 description 3
DCQROWYFLXIWEB-UHFFFAOYSA-N 2-chloro-1,3-benzothiazol-6-ol Chemical compound OC1=CC=C2N=C(Cl)SC2=C1 DCQROWYFLXIWEB-UHFFFAOYSA-N 0.000 description 3
NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
206010009900 Colitis ulcerative Diseases 0.000 description 3
208000011231 Crohn disease Diseases 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
206010026749 Mania Diseases 0.000 description 3
241001529936 Murinae Species 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
201000006704 Ulcerative Colitis Diseases 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
125000001246 bromo group Chemical group Br* 0.000 description 3
229910000024 caesium carbonate Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000002837 carbocyclic group Chemical group 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
239000003446 ligand Substances 0.000 description 3
206010025135 lupus erythematosus Diseases 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
PULIVVDOCBZLDC-UHFFFAOYSA-N n-phenyl-2-(pyridin-3-yloxymethyl)piperazine-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CNCC(COC=2C=NC=CC=2)N1C(=O)NC1=CC=CC=C1 PULIVVDOCBZLDC-UHFFFAOYSA-N 0.000 description 3
125000001624 naphthyl group Chemical group 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
208000008494 pericarditis Diseases 0.000 description 3
JCBJVAJGLKENNC-UHFFFAOYSA-M potassium ethyl xanthate Chemical compound [K+].CCOC([S-])=S JCBJVAJGLKENNC-UHFFFAOYSA-M 0.000 description 3
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
SRZLSAALBBCHRB-UHFFFAOYSA-N (3-phenyl-1,2-oxazol-5-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1C(C=2C=CC=CC=2)=NOC=1C(=O)N1CCNCC1COC1=CC=CN=C1 SRZLSAALBBCHRB-UHFFFAOYSA-N 0.000 description 2
WXQFHIXVEGWTFS-UHFFFAOYSA-N 1,4-bis(phenylmethoxycarbonyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(C(=O)OCC=2C=CC=CC=2)CCN1C(=O)OCC1=CC=CC=C1 WXQFHIXVEGWTFS-UHFFFAOYSA-N 0.000 description 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
ULDFRPKVIZMKJG-UHFFFAOYSA-N 2-amino-4-fluorophenol Chemical compound NC1=CC(F)=CC=C1O ULDFRPKVIZMKJG-UHFFFAOYSA-N 0.000 description 2
CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
VDXJKIZWLVTCGY-UHFFFAOYSA-N 2-chloro-6-propan-2-yloxy-1,3-benzothiazole Chemical compound CC(C)OC1=CC=C2N=C(Cl)SC2=C1 VDXJKIZWLVTCGY-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
JDPITNFDYXOKRM-UHFFFAOYSA-N 5-methoxy-3h-1,3-benzothiazole-2-thione Chemical compound COC1=CC=C2SC(=S)NC2=C1 JDPITNFDYXOKRM-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
208000004881 Amebiasis Diseases 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
206010001980 Amoebiasis Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
208000027496 Behcet disease Diseases 0.000 description 2
208000009137 Behcet syndrome Diseases 0.000 description 2
208000032841 Bulimia Diseases 0.000 description 2
206010006550 Bulimia nervosa Diseases 0.000 description 2
241000409333 Cabeza Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
206010007134 Candida infections Diseases 0.000 description 2
241000109539 Conchita Species 0.000 description 2
208000001490 Dengue Diseases 0.000 description 2
206010012310 Dengue fever Diseases 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241001663154 Electron Species 0.000 description 2
241000792859 Enema Species 0.000 description 2
208000004232 Enteritis Diseases 0.000 description 2
108010008165 Etanercept Proteins 0.000 description 2
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical group CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
206010016228 Fasciitis Diseases 0.000 description 2
201000006353 Filariasis Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
102000000849 HMGB Proteins Human genes 0.000 description 2
108010001860 HMGB Proteins Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical group CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
206010029240 Neuritis Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
229910002666 PdCl2 Inorganic materials 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
241001179982 Pimelodus grosskopfii Species 0.000 description 2
241000243142 Porifera Species 0.000 description 2
208000005107 Premature Birth Diseases 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
229910006069 SO3H Inorganic materials 0.000 description 2
244000180577 Sambucus australis Species 0.000 description 2
235000018734 Sambucus australis Nutrition 0.000 description 2
229920001800 Shellac Polymers 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
206010046914 Vaginal infection Diseases 0.000 description 2
201000008100 Vaginitis Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
229960002964 adalimumab Drugs 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
206010003230 arteritis Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
201000003984 candidiasis Diseases 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
229960003115 certolizumab pegol Drugs 0.000 description 2
PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
229940092727 claro Drugs 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
239000013058 crude material Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
208000025729 dengue disease Diseases 0.000 description 2
108700003601 dimethylglycine Proteins 0.000 description 2
208000007784 diverticulitis Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002451 electron ionisation mass spectrometry Methods 0.000 description 2
206010014665 endocarditis Diseases 0.000 description 2
239000007920 enema Substances 0.000 description 2
229940079360 enema for constipation Drugs 0.000 description 2
229960000403 etanercept Drugs 0.000 description 2
DNORZUSMZSZZKU-UHFFFAOYSA-N ethyl 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate Chemical compound C=1C=C(Cl)C=CC=1CCCCCC1(C(=O)OCC)CO1 DNORZUSMZSZZKU-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000002650 habitual effect Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
WNSDZBQLMGKPQS-UHFFFAOYSA-N hydron;piperazine-2-carboxylic acid;dichloride Chemical compound Cl.Cl.OC(=O)C1CNCCN1 WNSDZBQLMGKPQS-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000000185 intracerebroventricular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
239000011630 iodine Substances 0.000 description 2
SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
229960004125 ketoconazole Drugs 0.000 description 2
229950007278 lenercept Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
201000004792 malaria Diseases 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
229940078490 n,n-dimethylglycine Drugs 0.000 description 2
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
208000021722 neuropathic pain Diseases 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
125000001979 organolithium group Chemical group 0.000 description 2
ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
201000006292 polyarteritis nodosa Diseases 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
201000007094 prostatitis Diseases 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
208000013223 septicemia Diseases 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000004208 shellac Substances 0.000 description 2
229940113147 shellac Drugs 0.000 description 2
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
235000013874 shellac Nutrition 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
235000019345 sodium thiosulphate Nutrition 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
OORLZFUTLGXMEF-UHFFFAOYSA-N sulfentrazone Chemical compound O=C1N(C(F)F)C(C)=NN1C1=CC(NS(C)(=O)=O)=C(Cl)C=C1Cl OORLZFUTLGXMEF-UHFFFAOYSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
MWMPCRZJNLCAKQ-UHFFFAOYSA-N (2-fluoro-3-phenylphenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound FC1=C(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)C=CC=C1C1=CC=CC=C1 MWMPCRZJNLCAKQ-UHFFFAOYSA-N 0.000 description 1
WNSDZBQLMGKPQS-RZFWHQLPSA-N (2r)-piperazine-1,4-diium-2-carboxylic acid;dichloride Chemical compound Cl.Cl.OC(=O)[C@H]1CNCCN1 WNSDZBQLMGKPQS-RZFWHQLPSA-N 0.000 description 1
LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
WNSDZBQLMGKPQS-FHNDMYTFSA-N (2s)-piperazine-1,4-diium-2-carboxylic acid;dichloride Chemical compound Cl.Cl.OC(=O)[C@@H]1CNCCN1 WNSDZBQLMGKPQS-FHNDMYTFSA-N 0.000 description 1
COYRGDQAIYIZGD-UHFFFAOYSA-N (3-methoxyphenyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound COC1=CC=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1 COYRGDQAIYIZGD-UHFFFAOYSA-N 0.000 description 1
VITOBUFTGMNKPE-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone (1-phenylcyclopropyl)-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound Cc1cc(no1)C(=O)N1CCNCC1COc1cccnc1.O=C(N1CCNCC1COc1cccnc1)C1(CC1)c1ccccc1 VITOBUFTGMNKPE-UHFFFAOYSA-N 0.000 description 1
XGWIJUOSCAQSSV-XHDPSFHLSA-N (S,S)-hexythiazox Chemical compound S([C@H]([C@@H]1C)C=2C=CC(Cl)=CC=2)C(=O)N1C(=O)NC1CCCCC1 XGWIJUOSCAQSSV-XHDPSFHLSA-N 0.000 description 1
IMQNZDGCTFOEOF-UHFFFAOYSA-N 1,3-benzothiazol-2-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound N=1C2=CC=CC=C2SC=1C(=O)N1CCNCC1COC1=CC=CN=C1 IMQNZDGCTFOEOF-UHFFFAOYSA-N 0.000 description 1
ORIIXCOYEOIFSN-UHFFFAOYSA-N 1,3-benzothiazol-6-ol Chemical compound OC1=CC=C2N=CSC2=C1 ORIIXCOYEOIFSN-UHFFFAOYSA-N 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
DTSAARPZNAIVCM-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-(pyridin-3-yloxymethyl)piperazine Chemical compound ClC1=CC=CC(N2C(CNCC2)COC=2C=NC=CC=2)=C1 DTSAARPZNAIVCM-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
FBRIPJGYKYKYSP-UHFFFAOYSA-N 1-fluoro-2-phenylbenzene;2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound FC1=CC=CC=C1C1=CC=CC=C1.O=CN1CCNCC1COC1=CC=CN=C1 FBRIPJGYKYKYSP-UHFFFAOYSA-N 0.000 description 1
SQYQKIDYSFDHCG-UHFFFAOYSA-N 1-o-benzyl 4-o-tert-butyl 2-ethenylpiperazine-1,4-dicarboxylate Chemical compound C=CC1CN(C(=O)OC(C)(C)C)CCN1C(=O)OCC1=CC=CC=C1 SQYQKIDYSFDHCG-UHFFFAOYSA-N 0.000 description 1
KNEAWSKMVBSXNO-UHFFFAOYSA-N 1-o-benzyl 4-o-tert-butyl 2-formylpiperazine-1,4-dicarboxylate Chemical compound O=CC1CN(C(=O)OC(C)(C)C)CCN1C(=O)OCC1=CC=CC=C1 KNEAWSKMVBSXNO-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
IBNOPKCMNLPBNE-UHFFFAOYSA-N 1h-indol-3-yl-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C=1NC2=CC=CC=C2C=1C(=O)N1CCNCC1COC1=CC=CN=C1 IBNOPKCMNLPBNE-UHFFFAOYSA-N 0.000 description 1
HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
LHUHAARPMJISMM-UHFFFAOYSA-N 2,5-dichloro-1,3-benzothiazole Chemical compound ClC1=CC=C2SC(Cl)=NC2=C1 LHUHAARPMJISMM-UHFFFAOYSA-N 0.000 description 1
SYQJRAYJSBWYER-UHFFFAOYSA-N 2-(4-chlorophenoxy)-1-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]ethanone Chemical compound C1=CC(Cl)=CC=C1OCC(=O)N1C(COC=2C=NC=CC=2)CNCC1 SYQJRAYJSBWYER-UHFFFAOYSA-N 0.000 description 1
DUGSIPTZGZWKRX-UHFFFAOYSA-N 2-(pyridin-3-yloxymethyl)piperazine Chemical compound C1NCCNC1COC1=CC=CN=C1 DUGSIPTZGZWKRX-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
MCWDJCSYYQBUFW-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)-1,3-oxazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound FC1=CC=CC=C1C1=NC(C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=CO1 MCWDJCSYYQBUFW-UHFFFAOYSA-N 0.000 description 1
AKEHANAVSZAACW-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-1,3-oxazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C1=NC(C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=CO1 AKEHANAVSZAACW-UHFFFAOYSA-N 0.000 description 1
BXGJNORVWQBLTL-UHFFFAOYSA-N 2-[2-(4-methoxyphenyl)-1,3-oxazol-4-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C1=NC(C2(COC=3C=NC=CC=3)N(CCNC2)C=O)=CO1 BXGJNORVWQBLTL-UHFFFAOYSA-N 0.000 description 1
OBUSIOXKTKQQAQ-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-2-[3-(trifluoromethoxy)phenyl]-3h-1,3-oxazole-4-carbaldehyde Chemical compound FC(F)(F)OC1=CC=CC(C2(OC=C(C=O)N2)N2C(CNCC2)COC=2C=NC=CC=2)=C1 OBUSIOXKTKQQAQ-UHFFFAOYSA-N 0.000 description 1
YGKPIBYMLRCTRX-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-5-(trifluoromethyl)-1,3-benzoxazole Chemical compound N=1C2=CC(C(F)(F)F)=CC=C2OC=1N1CCNCC1COC1=CC=CN=C1 YGKPIBYMLRCTRX-UHFFFAOYSA-N 0.000 description 1
MBQMRDMGIZCSJI-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-5-[4-(trifluoromethyl)phenyl]-3h-furan-2-carbaldehyde Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CCC(N2C(CNCC2)COC=2C=NC=CC=2)(C=O)O1 MBQMRDMGIZCSJI-UHFFFAOYSA-N 0.000 description 1
XOPJAWHPKPMIKM-UHFFFAOYSA-N 2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-6-(trifluoromethoxy)-1,3-benzothiazole Chemical compound S1C2=CC(OC(F)(F)F)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 XOPJAWHPKPMIKM-UHFFFAOYSA-N 0.000 description 1
PXJQMKNTZWEXQW-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)pyridin-2-yl]-6-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(F)=CC=C1C1=CC=CN=C1C1N(C=O)C(COC=2C=NC=CC=2)CNC1 PXJQMKNTZWEXQW-UHFFFAOYSA-N 0.000 description 1
SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 description 1
AOWNYDDZDLTCGB-UHFFFAOYSA-N 2-amino-5-methoxyphenol Chemical compound COC1=CC=C(N)C(O)=C1 AOWNYDDZDLTCGB-UHFFFAOYSA-N 0.000 description 1
UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
BMTSZVZQNMNPCT-UHFFFAOYSA-N 2-aminopyridin-3-ol Chemical compound NC1=NC=CC=C1O BMTSZVZQNMNPCT-UHFFFAOYSA-N 0.000 description 1
PZDVFXUBTKPFSG-UHFFFAOYSA-N 2-bromo-5-(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=CC=C1Br PZDVFXUBTKPFSG-UHFFFAOYSA-N 0.000 description 1
FVUFTABOJFRHSU-UHFFFAOYSA-N 2-chloro-6-methoxy-1,3-benzothiazole Chemical compound COC1=CC=C2N=C(Cl)SC2=C1 FVUFTABOJFRHSU-UHFFFAOYSA-N 0.000 description 1
PAKSGYIFUVNJQF-UHFFFAOYSA-N 2-chloro-6-methyl-1,3-benzothiazole Chemical compound CC1=CC=C2N=C(Cl)SC2=C1 PAKSGYIFUVNJQF-UHFFFAOYSA-N 0.000 description 1
IIHQDQNLWWRBRM-UHFFFAOYSA-N 2-chloro-6-phenylmethoxy-1,3-benzothiazole Chemical compound C1=C2SC(Cl)=NC2=CC=C1OCC1=CC=CC=C1 IIHQDQNLWWRBRM-UHFFFAOYSA-N 0.000 description 1
RSDZXVRUWGEPQG-UHFFFAOYSA-N 2-chloro-[1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC(Cl)=NC2=N1 RSDZXVRUWGEPQG-UHFFFAOYSA-N 0.000 description 1
LPOLTKKVPDCFGA-UHFFFAOYSA-N 2-ethenylpiperazine-1,4-dicarboxylic acid Chemical compound OC(=O)N1CCN(C(O)=O)C(C=C)C1 LPOLTKKVPDCFGA-UHFFFAOYSA-N 0.000 description 1
125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
YCLQGAHLOJRZNQ-UHFFFAOYSA-N 2-formylpiperazine-1,4-dicarboxylic acid Chemical compound OC(=O)N1CCN(C(O)=O)C(C=O)C1 YCLQGAHLOJRZNQ-UHFFFAOYSA-N 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 description 1
RBCARPJOEUEZLS-UHFFFAOYSA-N 3-bromopyridin-2-amine Chemical compound NC1=NC=CC=C1Br RBCARPJOEUEZLS-UHFFFAOYSA-N 0.000 description 1
MRCYMFFGBZBELX-UHFFFAOYSA-N 3-formyl-4-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCN(C(O)=O)CC1C=O MRCYMFFGBZBELX-UHFFFAOYSA-N 0.000 description 1
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
WZMGQHIBXUAYGS-UHFFFAOYSA-N 3-hydroxy-6-methyl-2-nitropyridine Chemical compound CC1=CC=C(O)C([N+]([O-])=O)=N1 WZMGQHIBXUAYGS-UHFFFAOYSA-N 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
BALDUDYARYXJIK-UHFFFAOYSA-N 4,6-difluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(F)=CC(F)=C2N=C1N1CCNCC1COC1=CC=CN=C1 BALDUDYARYXJIK-UHFFFAOYSA-N 0.000 description 1
CVQWYMRSHHWLMH-UHFFFAOYSA-N 4-(4-methoxyphenyl)-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-thiazole;4-phenyl-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-thiazole Chemical compound C1NCCN(C=2SC=C(N=2)C=2C=CC=CC=2)C1COC1=CC=CN=C1.C1=CC(OC)=CC=C1C1=CSC(N2C(CNCC2)COC=2C=NC=CC=2)=N1 CVQWYMRSHHWLMH-UHFFFAOYSA-N 0.000 description 1
ABBOGKGLALOOFG-UHFFFAOYSA-N 4-chloro-5-methoxy-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound N=1C2=C(Cl)C(OC)=CC=C2SC=1N1CCNCC1COC1=CC=CN=C1 ABBOGKGLALOOFG-UHFFFAOYSA-N 0.000 description 1
ZHRLVDHMIJDWSS-UHFFFAOYSA-N 4-fluoro-2-nitrophenol Chemical compound OC1=CC=C(F)C=C1[N+]([O-])=O ZHRLVDHMIJDWSS-UHFFFAOYSA-N 0.000 description 1
ZOXHXRIKTZKGPP-UHFFFAOYSA-N 5-(4-methylphenyl)-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-3h-furan-2-carbaldehyde Chemical compound C1=CC(C)=CC=C1C1=CCC(N2C(CNCC2)COC=2C=NC=CC=2)(C=O)O1 ZOXHXRIKTZKGPP-UHFFFAOYSA-N 0.000 description 1
JUBFXGKAKNOSFS-UHFFFAOYSA-N 5-[3-(2-chlorophenyl)furan-2-yl]-2-(pyridin-3-yloxymethyl)piperazine-1-carbaldehyde Chemical compound ClC1=CC=CC=C1C1=C(C2NCC(COC=3C=NC=CC=3)N(C=O)C2)OC=C1 JUBFXGKAKNOSFS-UHFFFAOYSA-N 0.000 description 1
CWIPMXYDQDFBNA-UHFFFAOYSA-N 5-[3-(4-chlorophenyl)furan-2-yl]-2-(pyridin-2-yloxymethyl)piperazine-1-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1C1=C(C2NCC(COC=3N=CC=CC=3)N(C=O)C2)OC=C1 CWIPMXYDQDFBNA-UHFFFAOYSA-N 0.000 description 1
CVUONMXFTMDDCU-UHFFFAOYSA-N 5-chloro-2-methylsulfinyl-1,3-benzoxazole Chemical compound ClC1=CC=C2OC(S(=O)C)=NC2=C1 CVUONMXFTMDDCU-UHFFFAOYSA-N 0.000 description 1
NKYDKCVZNMNZCM-UHFFFAOYSA-N 5-chloro-3h-1,3-benzothiazole-2-thione Chemical compound ClC1=CC=C2SC(S)=NC2=C1 NKYDKCVZNMNZCM-UHFFFAOYSA-N 0.000 description 1
JARKOPXYLQFPBF-CQSZACIVSA-N 5-methyl-2-[(2r)-2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzoxazole Chemical compound C([C@H]1CNCCN1C=1OC2=CC=C(C=C2N=1)C)OC1=CC=CN=C1 JARKOPXYLQFPBF-CQSZACIVSA-N 0.000 description 1
SDINCKCSTRJMAY-UHFFFAOYSA-N 6-bromo-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(Br)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 SDINCKCSTRJMAY-UHFFFAOYSA-N 0.000 description 1
IJQSMNIZBBEBKI-UHFFFAOYSA-N 6-bromo-2-chloro-1,3-benzothiazole Chemical compound C1=C(Br)C=C2SC(Cl)=NC2=C1 IJQSMNIZBBEBKI-UHFFFAOYSA-N 0.000 description 1
HECJMTPEVWQFCY-UHFFFAOYSA-N 6-bromo-3h-1,3-benzothiazol-2-one Chemical compound BrC1=CC=C2NC(=O)SC2=C1 HECJMTPEVWQFCY-UHFFFAOYSA-N 0.000 description 1
BIZAMZKVTXRQKW-UHFFFAOYSA-N 6-chloro-2-methylsulfinyl-1,3-benzoxazole Chemical compound C1=C(Cl)C=C2OC(S(=O)C)=NC2=C1 BIZAMZKVTXRQKW-UHFFFAOYSA-N 0.000 description 1
OVJTVDMKFSMIMQ-UHFFFAOYSA-N 6-methoxy-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(OC)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 OVJTVDMKFSMIMQ-UHFFFAOYSA-N 0.000 description 1
AYQIMHBFVLZWKB-UHFFFAOYSA-N 6-methoxy-2-[2-[(6-methylpyridin-3-yl)oxymethyl]piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(OC)=CC=C2N=C1N1CCNCC1COC1=CC=C(C)N=C1 AYQIMHBFVLZWKB-UHFFFAOYSA-N 0.000 description 1
ZEIPATHNNKGIFH-UHFFFAOYSA-N 6-methoxy-3h-1,3-benzoxazole-2-thione Chemical compound COC1=CC=C2N=C(S)OC2=C1 ZEIPATHNNKGIFH-UHFFFAOYSA-N 0.000 description 1
DZWTXWPRWRLHIL-UHFFFAOYSA-N 6-methyl-1,3-benzothiazol-2-amine Chemical compound CC1=CC=C2N=C(N)SC2=C1 DZWTXWPRWRLHIL-UHFFFAOYSA-N 0.000 description 1
MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical compound CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 description 1
DENPGUJCWBRTFR-UHFFFAOYSA-N 6-propan-2-yloxy-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C2=CC(OC(C)C)=CC=C2N=C1N1CCNCC1COC1=CC=CN=C1 DENPGUJCWBRTFR-UHFFFAOYSA-N 0.000 description 1
HTSILHRAKGTJKR-UHFFFAOYSA-N 7-fluoro-2-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]-1,3-benzothiazole Chemical compound S1C=2C(F)=CC=CC=2N=C1N1CCNCC1COC1=CC=CN=C1 HTSILHRAKGTJKR-UHFFFAOYSA-N 0.000 description 1
206010000228 Abortion infected Diseases 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010003011 Appendicitis Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
241000206761 Bacillariophyta Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
YLLOJRIASIRXCZ-UHFFFAOYSA-N CC1(CC=C(N=C1)N)Br Chemical compound CC1(CC=C(N=C1)N)Br YLLOJRIASIRXCZ-UHFFFAOYSA-N 0.000 description 1
101100170172 Caenorhabditis elegans del-10 gene Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
206010008088 Cerebral artery embolism Diseases 0.000 description 1
108091005944 Cerulean Proteins 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
QOBCRGSDUXUBGD-UHFFFAOYSA-N Cl.Cl.N1C(CNCC1)C(=O)O.C(C)(C)(C)OC(=O)N1C(CN(CC1)C(=O)OC(C)(C)C)C(=O)O Chemical compound Cl.Cl.N1C(CNCC1)C(=O)O.C(C)(C)(C)OC(=O)N1C(CN(CC1)C(=O)OC(C)(C)C)C(=O)O QOBCRGSDUXUBGD-UHFFFAOYSA-N 0.000 description 1
206010009657 Clostridium difficile colitis Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009895 Colitis ischaemic Diseases 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
206010014096 Echinococciasis Diseases 0.000 description 1
208000009366 Echinococcosis Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000000289 Esophageal Achalasia Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
101100134922 Gallus gallus COR5 gene Proteins 0.000 description 1
244000287680 Garcinia dulcis Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020651 Hyperkinesia Diseases 0.000 description 1
208000000269 Hyperkinesis Diseases 0.000 description 1
206010020741 Hyperpyrexia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
208000010159 IgA glomerulonephritis Diseases 0.000 description 1
206010021263 IgA nephropathy Diseases 0.000 description 1
208000024781 Immune Complex disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
241000408529 Libra Species 0.000 description 1
241001134453 Lista Species 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
238000006751 Mitsunobu reaction Methods 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
241000604231 Oblea Species 0.000 description 1
206010030136 Oesophageal achalasia Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
206010037128 Pseudomembranous colitis Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
208000005793 Restless legs syndrome Diseases 0.000 description 1
208000002359 Septic Abortion Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
241000244317 Tillandsia usneoides Species 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
208000027207 Whipple disease Diseases 0.000 description 1
208000018839 Wilson disease Diseases 0.000 description 1
AUGRRNWUDPBHDO-UHFFFAOYSA-N [3-(4-chlorophenyl)phenyl]-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)=C1 AUGRRNWUDPBHDO-UHFFFAOYSA-N 0.000 description 1
MVGKPHVNPMOSOH-UHFFFAOYSA-N [4-(4-fluorophenyl)phenyl]-[2-(pyridin-3-yloxymethyl)piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1=CC=C(C(=O)N2C(CNCC2)COC=2C=NC=CC=2)C=C1 MVGKPHVNPMOSOH-UHFFFAOYSA-N 0.000 description 1
KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
201000000621 achalasia Diseases 0.000 description 1
YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
125000005604 azodicarboxylate group Chemical group 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
235000020299 breve Nutrition 0.000 description 1
238000005282 brightening Methods 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
UKLJMHXGZUJRTL-UHFFFAOYSA-L calcium;n-cyclohexylsulfamate Chemical compound [Ca+2].[O-]S(=O)(=O)NC1CCCCC1.[O-]S(=O)(=O)NC1CCCCC1 UKLJMHXGZUJRTL-UHFFFAOYSA-L 0.000 description 1
244000309466 calf Species 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
239000012069 chiral reagent Substances 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
TXCFQKQBPSGAKK-UHFFFAOYSA-N ditert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C(CO)C1 TXCFQKQBPSGAKK-UHFFFAOYSA-N 0.000 description 1
BYGMEAQCXLANNP-UHFFFAOYSA-N ditert-butyl 2-formylpiperazine-1,4-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C(C=O)C1 BYGMEAQCXLANNP-UHFFFAOYSA-N 0.000 description 1
UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000000132 electrospray ionisation Methods 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
208000003401 eosinophilic granuloma Diseases 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
208000001606 epiglottitis Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000005286 illumination Methods 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
201000010849 intracranial embolism Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
201000008222 ischemic colitis Diseases 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
VHVPQPYKVGDNFY-ZPGVKDDISA-N itraconazole Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-ZPGVKDDISA-N 0.000 description 1
229960004130 itraconazole Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
230000028252 learning or memory Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
229960002329 methacholine Drugs 0.000 description 1
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
MHCVFONCELCCTK-UHFFFAOYSA-N n-(3-chloro-4-methoxyphenyl)-2-[(pyridin-3-ylamino)methyl]piperazine-1-carboxamide Chemical compound C1=C(Cl)C(OC)=CC=C1NC(=O)N1C(CNC=2C=NC=CC=2)CNCC1 MHCVFONCELCCTK-UHFFFAOYSA-N 0.000 description 1
PNYVFWFDLOHXIV-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(pyridin-3-ylmethyl)piperazine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)N1C(CC=2C=NC=CC=2)CNCC1 PNYVFWFDLOHXIV-UHFFFAOYSA-N 0.000 description 1
HWPDXLBUKLARJG-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[(3-fluorophenoxy)methyl]piperazine-1-carboxamide Chemical compound FC1=CC=CC(OCC2N(CCNC2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 HWPDXLBUKLARJG-UHFFFAOYSA-N 0.000 description 1
NLWZKEGCXLWVEU-UHFFFAOYSA-N n-(4-methoxyphenyl)-2-(pyridin-3-ylmethyl)piperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1C(CC=2C=NC=CC=2)CNCC1 NLWZKEGCXLWVEU-UHFFFAOYSA-N 0.000 description 1
PFHVGSCAFKJJQC-UHFFFAOYSA-N n-(4-methoxyphenyl)-3-(phenoxymethyl)piperidine-4-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1C(COC=2C=CC=CC=2)CNCC1 PFHVGSCAFKJJQC-UHFFFAOYSA-N 0.000 description 1
TYEFGSGQYJLMIT-UHFFFAOYSA-N n-(4-methoxyphenyl)piperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1CCNCC1 TYEFGSGQYJLMIT-UHFFFAOYSA-N 0.000 description 1
LIIVUMYUXKKWGQ-UHFFFAOYSA-N n-[(1-pyrimidin-2-ylpiperazin-2-yl)methyl]pyridin-3-amine Chemical compound C1NCCN(C=2N=CC=CN=2)C1CNC1=CC=CN=C1 LIIVUMYUXKKWGQ-UHFFFAOYSA-N 0.000 description 1
CJJZCWJJAZMVCJ-UHFFFAOYSA-N n-benzyl-2,5-dimethylaniline Chemical compound CC1=CC=C(C)C(NCC=2C=CC=CC=2)=C1 CJJZCWJJAZMVCJ-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
208000015706 neuroendocrine disease Diseases 0.000 description 1
210000000715 neuromuscular junction Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
235000015927 pasta Nutrition 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008249 pharmaceutical aerosol Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
239000006187 pill Substances 0.000 description 1
JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 description 1
BRYCUMKDWMEGMK-UHFFFAOYSA-N piperazine-2-carboxamide Chemical class NC(=O)C1CNCCN1 BRYCUMKDWMEGMK-UHFFFAOYSA-N 0.000 description 1
KIUVRQJNCIUBJN-UHFFFAOYSA-N piperazine-2-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1CNCCN1 KIUVRQJNCIUBJN-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
208000008423 pleurisy Diseases 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229940114930 potassium stearate Drugs 0.000 description 1
ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
UXWXUWMFAJKIMS-UHFFFAOYSA-N potassium;pyridin-3-ol Chemical compound [K].OC1=CC=CN=C1 UXWXUWMFAJKIMS-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
206010036596 premature ejaculation Diseases 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
239000008213 purified water Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
108010014374 puros Proteins 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000000376 reactant Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
RCVANPPRWRQKCK-LBPRGKRZSA-N tert-butyl (3s)-3-(pyridin-3-yloxymethyl)piperazine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN[C@@H]1COC1=CC=CN=C1 RCVANPPRWRQKCK-LBPRGKRZSA-N 0.000 description 1
XRHZUJFKOADGMB-UHFFFAOYSA-N tert-butyl 3-(2-pyridin-3-ylethyl)piperazine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCNC1CCC1=CC=CN=C1 XRHZUJFKOADGMB-UHFFFAOYSA-N 0.000 description 1
ZRUDQBDZNIJOAY-UHFFFAOYSA-N tert-butyl 3-(pyridin-3-ylmethyl)piperazine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCNC1CC1=CC=CN=C1 ZRUDQBDZNIJOAY-UHFFFAOYSA-N 0.000 description 1
OZOBSYYMOJNERD-UHFFFAOYSA-N tert-butyl 4-(phenylcarbamoyl)-3-(pyridin-3-yloxymethyl)piperazine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN(C(=O)NC=2C=CC=CC=2)C1COC1=CC=CN=C1 OZOBSYYMOJNERD-UHFFFAOYSA-N 0.000 description 1
IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
208000025883 type III hypersensitivity disease Diseases 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

ES07809388.7T 2006-06-06 2007-06-06 Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas Active ES2498043T3 (es)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US81127506P	2006-06-06	2006-06-06
US811275P		2006-06-06
US85283606P	2006-10-19	2006-10-19
US852836P		2006-10-19
US90124007P	2007-02-13	2007-02-13
US901240P		2007-02-13
PCT/US2007/013425 WO2007146066A2 (fr)	2006-06-06	2007-06-06	Nouvelles pipérazines, compositions pharmaceutiques et procédés d'utilisation de celles-ci

Publications (1)

Publication Number	Publication Date
ES2498043T3 true ES2498043T3 (es)	2014-09-24

Family

ID=38658579

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES07809388.7T Active ES2498043T3 (es)	2006-06-06	2007-06-06	Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas

Country Status (5)

Country	Link
EP (1)	EP2044038B1 (fr)
JP (2)	JP5363315B2 (fr)
CA (1)	CA2659512C (fr)
ES (1)	ES2498043T3 (fr)
WO (1)	WO2007146066A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5363315B2 (ja) *	2006-06-06	2013-12-11	コーナーストーンセラピューティクスインコーポレイテッド	新規ピペラジン、医薬組成物、およびその使用方法
MX2010004499A (es)	2007-10-24	2010-05-20	Astellas Pharma Inc	Compuesto de azolcarboxamida o sal de el.
JO2911B1 (en)	2008-04-11	2015-09-15	جانسن فارمسيتكا ان في	Thiazoloperidine-2-amoxicillinyl-phenyl and thiazoloperazine-2-amoxicillinyl phenyl amine as agents for the control of leukotrien A4 hydrolase
JP5605844B2 (ja)	2008-10-17	2014-10-15	塩野義製薬株式会社	血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体
KR101051077B1 (ko) *	2008-12-05	2011-07-21	한국화학연구원	2-피페라지노-4,5-이중치환-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제
EP2430019B1 (fr)	2009-05-14	2013-09-18	Janssen Pharmaceutica, N.V.	Composes comprenant deux restes hétéroaryle bicycliques en tant que modulateurs de leukotriene a4 hydrolase
AU2010291834A1 (en) *	2009-09-04	2012-03-15	Zalicus Pharmaceuticals Ltd.	Substituted heterocyclic derivatives for the treatment of pain and epilepsy
TWI558398B (zh)	2009-09-22	2016-11-21	諾華公司	菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011152442A1 (fr) *	2010-06-03	2011-12-08	塩野義製薬株式会社	Procédé de production de 2‑chloro-6-fluorobenzoxazole
US20140113824A1 (en)	2011-05-10	2014-04-24	Bayer Intellectual Property Gmbh	Bicyclic (thio)carbonylamidines
JP6463631B2 (ja)	2011-06-09	2019-02-06	ライゼン・ファーマシューティカルズ・エスアー	Ｇｐｒ−１１９のモジュレータとしての新規化合物
EP2961403A4 (fr)	2013-03-01	2016-11-30	Zalicus Pharmaceuticals Ltd	Inhibiteurs hétérocycliques du canal sodique
MY191087A (en)	2013-03-15	2022-05-30	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
TWI670267B (zh) *	2013-07-10	2019-09-01	日商明治製菓藥業股份有限公司	新穎ｐｄｅ４抑制劑
EA202092627A1 (ru)	2013-11-18	2021-09-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
GB201401886D0 (en)	2014-02-04	2014-03-19	Lytix Biopharma As	Neurodegenerative therapies
FR3022784B1 (fr) *	2014-06-26	2017-09-08	Ecole Normale Superieure Lyon	Sondes moleculaires activables hydrosolubles, intermediaires pour leur synthese et procedes de detection associes
CN112920137A (zh) *	2021-03-02	2021-06-08	南京波普生物医药研发有限公司	噻唑医药中间体合成工艺
CN117003710A (zh) *	2023-07-19	2023-11-07	镇江先锋植保科技有限公司	一种2-巯基-6-氯苯并恶唑的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2165176A1 (fr) *	1993-06-18	1995-01-05	Samuel L. Graham	Inhibiteurs de la farnesyl-proteine transferase
IL117798A (en) *	1995-04-07	2001-11-25	Schering Plough Corp	Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
MX9707561A (es) *	1995-04-07	1997-12-31	Schering Corp	Compuestos de carbonil piperazinilo y piperidinilo.
US5880128A (en) *	1996-05-08	1999-03-09	Schering Corporation	Carbonyl piperazinyl and piperidinyl compounds
US5929077A (en) *	1996-11-08	1999-07-27	Leftheris; Katerina	Thioproline-containing inhibitors of farnesyl protein transferase
US6372747B1 (en) *	1998-12-18	2002-04-16	Schering Corporation	Farnesyl protein transferase inhibitors
US6878700B1 (en) *	1998-12-29	2005-04-12	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US20030073681A1 (en) *	2001-08-21	2003-04-17	Hauske James R.	2-substituted piperidines that are ligands for monoamine receptors and transporters
JP4825664B2 (ja) *	2003-02-14	2011-11-30	メルクセローノソシエテアノニム	ピペラジン−２−カルボキサミド誘導体
WO2006014012A2 (fr) *	2004-08-06	2006-02-09	Otsuka Pharmaceutical Co., Ltd.	Compose aromatique
JP5363315B2 (ja) *	2006-06-06	2013-12-11	コーナーストーンセラピューティクスインコーポレイテッド	新規ピペラジン、医薬組成物、およびその使用方法

2007
- 2007-06-06 JP JP2009514375A patent/JP5363315B2/ja not_active Expired - Fee Related
- 2007-06-06 WO PCT/US2007/013425 patent/WO2007146066A2/fr active Application Filing
- 2007-06-06 EP EP07809388.7A patent/EP2044038B1/fr not_active Not-in-force
- 2007-06-06 CA CA2659512A patent/CA2659512C/fr not_active Expired - Fee Related
- 2007-06-06 ES ES07809388.7T patent/ES2498043T3/es active Active
2013
- 2013-06-14 JP JP2013125127A patent/JP2013199489A/ja active Pending

Also Published As

Publication number	Publication date
EP2044038A2 (fr)	2009-04-08
CA2659512A1 (fr)	2007-12-21
CA2659512C (fr)	2015-09-08
WO2007146066A2 (fr)	2007-12-21
JP5363315B2 (ja)	2013-12-11
JP2009539848A (ja)	2009-11-19
WO2007146066A3 (fr)	2008-02-14
EP2044038B1 (fr)	2014-07-02
JP2013199489A (ja)	2013-10-03

Publication	Publication Date	Title
ES2498043T3 (es)	2014-09-24	Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas
CA2703824C (fr)	2016-06-07	Modulateurs pour l'amyloide-beta
ES2513915T3 (es)	2014-10-27	Inhibidores de la tirosina quinasa de Bruton
CA2605899C (fr)	2011-02-08	Derives de triazole utilises comme antagonistes de la vasopressine
AU2018379321B2 (en)	2024-05-16	1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
WO2006093247A1 (fr)	2006-09-08	NOUVEAU COMPOSÉ AMINOPYRIDINE AYANT UNE ACTIVITÉ D'INHIBITION DE LA Syk
TWI838430B (zh)	2024-04-11	作為vanin抑制劑之雜芳族化合物
US20170136007A1 (en)	2017-05-18	Novel piperazines, pharmaceutical compositions and methods of use thereof
BRPI0620196A2 (pt)	2013-01-15	composto, processo para a preparaÇço do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para a produÇço de um efeito antibacteriano em um animal de sangue quente, para a inibiÇço de dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente e para o tratamento de uma infecÇço bacteriana em um animal de sangue quente
US10364255B2 (en)	2019-07-30	Heteroaromatic compounds as Vanin inhibitors
MX2011008308A (es)	2011-11-02	Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica.
US20120101110A1 (en)	2012-04-26	Diaza-spiro[5.5]undecanes
ES2435076T3 (es)	2013-12-18	Compuestos 4,5,6,7-tetrahidro-isoxazolo[4,5-c]piridina sustituidos y su utilización para la producción de medicamentos
ES2839407T3 (es)	2021-07-05	Antagonistas del receptor de dopamina D3 que tienen una unidad estructural morfolina
ES2378861T3 (es)	2012-04-18	Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
RU2797613C2 (ru)	2023-06-07	Производные 1,2,4-оксадиазола в качестве ингибиторов гистондезацетилазы 6
EP3587411B1 (fr)	2021-01-27	Dérivés de 1-(alpha-méthylbenzyl)-5-(pipéridinométhyl)imidazole et leurs utilisations pour améliorer les propriétés pharmacocinétiques d'un médicament